Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles

After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.